tbuckley/cabot-search huggingface dataset:
AB1562-HPR NEUTROPHIL TO LYMPHOCYTE RATIO AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH KNEE OSTEOARTHRITIS
Authors: G. Qader
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Knee osteoarthritis is a debilitating inflammatory disease that affects the quality of life of people, especially the elderly. One of the markers is the neutrophil lymphocyte ratio (NLR) which can be used to monitor disease activity and determine inflammatory disease progression and treatment effectiveness. <h3>Objectives:</h3> This study was performed to evaluate the neutrophils lymphocytes ratio as an marker of disease activity in patients with osteoarthritis of the knee. <h3>Methods:</h3> This study is a cross-sectional study that was performed in October 2021 to April 2022 on 100 patients with knee osteoarthritis referred to the Rheumatology Clinic of Rizgari Teaching Hospital in Erbil. Data were collected using a questionnaire that included three sections: demographics, medical history, and test results for inflammatory markers. Descriptive and linear regression tests were used to analyze the data. <h3>Results:</h3> Examination of patients' clinical status showed that 99 (99%) people have knee pain, In terms of limb involvement and limb pain, 22% reported pain in the right leg. Also 22% reported pain in the left leg and 56% reported pain and involvement in both legs. The mean of NLR = 2.045 (1.373) CI 95%, 1.770 - 2.31 was obtained. The results of linear regression the relationship between NLR and pain intensity in patients has been reported directly. <h3>Conclusion:</h3> According to the findings of the present study, it seems that the neutrophil to lymphocyte ratio (NLR) can be used as a marker in assessing the severity and activity of osteoarthritis (OA). Considering this finding of the present study and also the findings of similar studies on the existence of a relationship between the ratio of neutrophils to lymphocytes and osteoarthritis, this ratio can be considered as a promising marker for early diagnosis and treatment of osteoarthritis (OA). And it can be used routinely in clinics and laboratory wards to diagnose the disease. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Grateful thanks to Dashty Abbas Albustany, Assistant Professor, Hawler Medical University, Erbil, Kurdistan Region, Iraq, all staff members at Rheumatology Unit, And all patients Participated in this studt <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1588-HPR EFFECTIVENESS OF GLOBAL POSTURAL REEDUCATION IN CHRONIC LOW BACK PAIN
Authors: Z. Syrine, S. Bouden, R. Leila, A. Ben Tekaya, I. Mahmoud, R. Tekaya, O. Saidane, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Chronic low back pain (LBP) is one of the most common musculoskeletal disorders. It represents a healthcare issue as it is often associated with loss of work productivity and thus huge economic burden. Several physiotherapeutic strategies may be used during the treatment. <h3>Objectives:</h3> To compare global postural reeducation (GPR) to a conventional rehabilitation protocol for improving pain, flexibility, function, and psychological impact in patients with chronic LBP. <h3>Methods:</h3> A randomized, controlled, clinical trial with a single blinded examiner was conducted. Patients with chronic LBP were randomly allocated to 2 groups: group control received the conventional rehabilitation protocol alone and group GPR received the conventional protocol associated to GPR. Both groups were followed a 3 sessions per week over a period of 4 weeks. Evaluations were performed at the start of the study and 4 weeks after. We used the Oswestry scale to assess disability, visual analog scale (VAS) to evaluate pain and the Hospital Anxiety Depression the (HAD) scale in its Arabic validated version to evaluate depression. <h3>Results:</h3> We included 26 patients with common LBP (13 in the control group and 13 in the GPR group). Mean age was 45 years in the control group and 46 years in the GPR group. Mean duration of back pain was 18 months. Mean body weight was 73kg [60-88] in the control group and 72kg [60-87] in the GPR group. 84.61% were obese or overweight (BMI&gt;25). All the patients had a sedentary lifestyle. The GPR associated group demonstrated significant statistical improvements in the VAS (p=0.01), lumbar mobility (p=0.02) and Oswestry scale (p=0.04) at the four weeks' evaluation. Likewise HAD score decreased significantly in the GPR group (11 to 3.6; p=0.01). <h3>Conclusion:</h3> GPR associated to the conventional rehabilitation seems to be an effective tool in the management of common LBP and its related psychological impact. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1546-HPR PSYCHOMETRIC EVALUATION OF THE SERBIAN ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE AND ITS CORRELATIONS WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS
Authors: D. Dudok, M. Zlatkovic-Svenda, J. Thorpe, J. Milicevic, D. Petrovic, M. Zdravković, G. Radunovic
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire gauges the impact of ankylosing spondylitis on individuals' overall well-being, shedding light on the quality of life challenges associated with this condition. <h3>Objectives:</h3> To examine psychometric properties of the Serbian version of the ASQoL and to evaluate its correlations with AS disease activity and functional status indexes. <h3>Methods:</h3> After translation with transcultural validation and cognitive debriefing interview in 10 randomly chosen persons was successfully done, 60 patients were recruited consecutively, as they entered the Institute of Rheumatology for a regular check-up and tested in two occasions two weeks apart to evaluate the ASQoL psychometric properties. Construct validity was assessed through convergent validity, using Notthingham Health Profile as a comparator and a known-group validity by comparisons with self-perceived disease activity and overall health. Internal reliability was determined by calculating Cronbach's alpha coefficient. External validity was assessed by test-retest reliability. Also, correlations of the ASQoL with ASDAS, BASFI, BASDAI, respiratory index, Schober's test and SPARCC index were determined <h3>Results:</h3> There was a significant correlation between the ASQoL and NHP domains of pain (r=0.79), emotional reactions (r=0.78), physical activity (r=0.77) and energy (r=0.75). Cronbach alpha coefficents of 0.95 and 0.91 in Visit 1 and Visit 2, respectively, indicated adequate internal reliability. ASQoL showed minimal levels of random error and good test-retest reliability, with a Spearman correlation coefficient of 0.84. Serbian ASQoL was able to differentiate between patients with varying perceived general health status (p&lt;0.05) and disease severity (p&lt;0.05). Statistically significant correlations between ASQoL and ASDAS, BASDAI and BASFI were also demonstrated (p&lt;0.001), whereas correlations with respiratory index, Schober's test and SPARCC index were insignificant. <h3>Conclusion:</h3> The Serbian version of the ASQoL demonstrated excellent psychometric properties, and good corelations with disease activity and functional status indexes, affirming its validity as a reliable tool suitable for both clinical research and routine clinical usage. Figure 1. Table showcasing correlations between Serbian Ankylosing Spondylitis Quality of Life and different Nottingham Health Profile domains, as well as results of internal and external reliability <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1533 ANTI-RO52 POSITIVITY IS ASSOCIATED WITH POORER LUNG FUNCTION AT DIAGNOSIS IN CONNECTIVE TISSUE DISEASE AND IDIOPATHIC INFLAMMATORY MYOPATHY ASSOCIATED INTERSTITIAL LUNG DISEASE
Authors: R. Harrington, R. Conway, R. Fahy
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Anti-Ro52 antibodies are detectable in multiple connective tissue diseases, particularly Sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis, as well as in idiopathic inflammatory myopathies (IIM). Recent cohort studies in these patients suggest an association with anti-Ro52 positivity and more progressive interstitial lung disease (ILD) with increased morbidity and mortality. <h3>Objectives:</h3> We sought to investigate the significance of anti-Ro52 positivity in an Irish population of CTD-ILD and IIM-ILD patients. <h3>Methods:</h3> This is a monocentric 7-year retrospective combined cohort study of CTD-ILD and IIM-ILD patients treated in a specialist ILD centre. We screened 781 extended myositis panel results from 2016 to 2022 to identify a cohort of 41 CTD-ILD and IIM-ILD patients. <h3>Results:</h3> The screening process identified 41 CTD-ILD and IIM-ILD patients, (19 male, 22 female) with a mean age of 66.7 (std±13.2) and a mean disease duration of 4.4 years (std±2.6). 14 patients demonstrated anti-Ro52 antibody positivity compared with 27 who did not. The anti-Ro52+ cohort had a significantly lower baseline diffusing capacity for carbon monoxide (DLCO) at diagnosis at 41.70% predicted compared with 55.41% predicted for the anti-Ro52- cohort (p = 0.009). Baseline forced vital capacity (FVC) was numerically lower in the anti-Ro52+ cohort at 75.78% predicted versus 92.83% predicted but this did not reach statistical significance (p = 0.083). After standard of care treatment with immunosuppressive and anti-fibrotic therapies, the anti-Ro52+ cohort had comparatively poorer FVCs on their most recent pulmonary function tests (PFTs) at 72.16% predicted versus 97.06% predicted (p = 0.028). Despite relatively poorer lung function 11/14 anti-Ro52+ patients are alive today compared with 23/27 anti-Ro52- patients (p = 0.593). There was no demonstrable association between anti-Ro52 status and smoking, malignancy or ILD pattern on computed tomography (CT). Interestingly, the subgroup of patients under 65 presented with lower baseline FVC at diagnosis when compared with those over 65; 75.45% predicted vs. 95.6% predicted (p = 0.026). One hypothesis is that the younger patient is at greater risk of fulminant disease onset compared with more insidious disease progression in elderly patients. <h3>Conclusion:</h3> Anti-Ro52 antibodies are associated with a lower DLCO at diagnosis of CTD-ILD and IIM-ILD in an Irish cohort of patients. Patients under 65 also presented with a more markedly reduced FVC than those over 65, perhaps reflecting the fulminant nature of disease onset in this less elderly demographic. REFERENCES: NIL. <h3>Acknowledgements:</h3> Department of Rheumatology, Department of Respiratory Medicine, Pulmonary Function Testing Laboratory, Immunology Laboratory. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1554-HPR INVESTIGATION OF RELATIONSHIPS BETWEEN WORK ABILITY AND WORK VARIABLES IN EMPLOYED PEOPLE WITH ARTHRITIS
Authors: S. Yardim, S. Y. Cetin, A. Ayan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Arthritis is inflammation seen in the joint and is reflected in the individual's life as acute or chronic pain, edema, sensitivity and loss of function in the relevant joint [1]. If the individual is an employee, patient's present abilities and degree of work ability are likewise impacted [2]. Individuals' levels of ability at work are influenced by their socioeconomic situation, arthritis-related symptoms and employment-related factors [3]. There was no study that investigation of work ability in employed people with arthritis. <h3>Objectives:</h3> The aim of this study was to investigate work abilities of employed people with arthritis. <h3>Methods:</h3> 154 employed people with arthritis (132 female, 22 male) with an average age of 52,31±11,21 were included in this study. Work Ability Index (WAI) was used to evaluate the work ability and a form was used about work varieties. <h3>Results:</h3> According to results, low significant negative correlations were found duration of illness, age, presence of shift and WAI (r:-0.285, r:-0.394, r:-0.253) (p:0.00, 0.00, 0.02), modarate significant positive correlations were observed education level and WAI (r:0.457) (p:0.00) and low significant positive correlations were observed income level, presence of business travel and WAI (r:0.230, r:0.166) (p:0.00, 0.03). <h3>Conclusion:</h3> According to this study, while the duration of illness, age, shift duration increased; work ability decreased. While the duration of education, level of income and business travel increased, work ability increased. To evaluate the work ability and related problems of individual with arthritis is important in determining occupational rehabilitation programs. <h3>REFERENCES:</h3> [1] Cross M., Smith E., Hoy D., et all The Global Burden of Rheumatoid Arthritis:Estimates From The Global Burden of Disease 2010 study. Ann Rheum Dis,73,1316-22. [2] Sokka T. 2003 Work Disability in Early Rheumatoid Arthritis. Clin Exp Rheumatol,21,S71-4. [3] Berner C., Haider S., Grabovac I., et all Work Ability and Employment in Rheumatoid Arthritis: A Cross-Sectional Study on the Role of Muscle Strength and Lower Extremity Function. Int j Rheumatol, 2018,3756207. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1534 CHARTING EXCELLENCE: DISCOVERING VALUABLE INSIGHTS THROUGH A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF IN-PATIENT RHEUMATOLOGY REGISTRIES
Authors: C. L. Tan, A. H. Ramlan, S. C. Ng, C. H. Lim
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Patients diagnosed with rheumatic and musculoskeletal diseases (RMD) often necessitate in-patient care for a variety of reasons, including treatment for symptom exacerbation, disease flare-ups, disease or treatment complications. In contrast to those requiring outpatient care, these patients typically present with more severe and complex diseases, often associated with higher mortality rates. <h3>Objectives:</h3> Our hospital serves as the tertiary referral center for rheumatology services in the northern states of Malaysia. These regions exhibit lower household incomes, limited resources, and are predominantly rural compared to urban areas. Our objective is to analyze our in-patient rheumatology service, delving into patient demographics, diagnosis, and in-patient mortality. <h3>Methods:</h3> We retrospectively analyze our in-patient registries and referrals from April 2017 to December 2023, focusing on patient demographics, rheumatology diagnosis, and discharge status. In-patient mortality, referring to death occurring during a patient's hospital stay, was specifically examined. It involved detailed reviews of clinical notes, blood investigations, medications, and the cause of death. The dataset was then analyzed using statistical software. <h3>Results:</h3> A total of 2276 patients received treatment during these periods. Commonly encountered diagnosis included systemic lupus erythematosus (SLE) n= 926 (40.7%), gouty arthritis n= 408 (17.9%), inflammatory arthritis n= 273 (12%) (including rheumatoid arthritis n= 156), vasculitis n= 110 (4.8%), systemic sclerosis n= 83 (3.6%), and idiopathic inflammatory myositis n= 46 (2%). There were more female patients n= 1556 (68.3%) compared to male patients n= 722 (31.7%). 79 patients required intensive care unit or cardiac care unit admission during this period for ventilatory support, or renal replacement therapy. Common referrals were from the medical department (74%), surgical department (7%), obstetrics &amp; gynecology department (6%), cardiology department (5%), orthopedics department (4%), and respiratory department (4%). There were 95 (4.2%) in-patient mortality; with a median age of 51 years. The primary causes of death were infections n= 60 (63.2%), followed by active disease n= 18 (18.9%), cardiovascular events n= 12 (12.6%), malignancy n= 3 (3.2%), and upper gastrointestinal bleeding n= 2 (2.1%). <h3>Conclusion:</h3> In our cohort of patients, infections emerged as the most prevalent cause of death, followed by active disease and cardiovascular complication. Our finding is consistent with previously published studies. This valuable insight emphasizes the need for increased vigilance in improving strategies for the management and prevention of infections among individuals with RMD. REFERENCES: NIL. <h3>Acknowledgements:</h3> Dr Tan Chou Luan. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: A post hoc analysis.
Authors: Dulce Ramirez, Lipeng Chen, Jun Zhang, Wassim Aldairy, William B. White
Journal: Journal of Clinical Oncology (2024)

e19016 Background: Bruton tyrosine kinase (BTK) inhibitors are an important therapeutic option for patients with CLL/SLL. The first-generation BTK inhibitor, ibrutinib (ibru), is associated with an increased risk of hypertension. Zanubrutinib (zanu) is a next-generation BTK inhibitor designed to maximize BTK occupancy and minimize toxicity with fewer off-target effects. This analysis evaluated the risk of developing hypertension based on initiation of antihypertensives (anti-HTN) in ALPINE (NCT03734016). Methods: Anti-HTN use in the zanu (n=324) and ibru (n=324) treatment arms was assessed. The definition of anti-HTN was based on Standardized Drug Grouping; concomitant anti-HTN were adjudicated by an independent hypertension specialist blinded to BTK inhibitor assignment. Time to initiating new anti-HTN and time to adding a new class of anti-HTN were assessed using the Kaplan-Meier method. Comparisons of time-to-onset endpoints were analyzed based on the log-rank test. Results: At baseline, patient characteristics were generally balanced between zanu and ibru arms (median age, 66.7 vs 67.1 y; male, 65.1% vs 71.4%; history of hypertension, 50.9% vs 50.0%; type 2 diabetes mellitus, 10.1% vs 8.9%). Among patients not on anti-HTN at baseline, 20.7% (n=35/169) of zanu- and 28.7% (n=51/178) of ibru-treated patients initiated anti-HTN during the study. Among all patients, fewer patients in the zanu arm initiated new anti-HTN (28.4% [n=92/324] vs 32.4% [n=105/324]) and the anti-HTN were initiated later (hazard ratio [HR], 0.77; P-value=.071). Additionally, statistically fewer patients in the zanu arm compared with the ibru arm started anti-HTN in a new class (24.1% [n=78/324] vs 29.3% [n=95/324]) and the anti-HTN were started later (HR, 0.72; P-value=.034). The event rates for initiation of new anti-HTN or a new class of anti-HTN were consistently lower in the zanu vs ibru arm at each timepoint (Table). Conclusions: In ALPINE, initiation of new anti-HTN or a new class of anti-HTN occurred less frequently in the zanu arm vs the ibru arm in patients with CLL/SLL. Adoption of anti-HTN occurred sooner with ibru than zanu. These findings should be considered when initiating BTK inhibitor therapy in patients with CLL/SLL who have an elevated cardiovascular risk. Clinical trial information: NCT03734016 . [Table: see text]
AB1586-HPR REASONS FOR STOPPING HYDROXYCHLOROQUINE: DO WE GIVE UP EASILY?
Authors: B. Armagan, H. E. Konak, E. Atalar, B. Özdemir Ulusoy, P. Akyüz Dağli, Ö. Karakaş, S. Esmer, H. Apaydin, M. A. Eksin, B. Polat, R. Kocak Ulucaköy, E. Kayacan Erdoğan, S. C. Güven, K. Orhan, İ. Dogan, H. Babaoglu, Y. Maraş
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Hydroxychloroquine (HCQ) is a disease-modifying agent in the treatment of many rheumatologic diseases. HCQ treatment may be discontinued by patients and physicians due to dermatologic, cardiovascular or gastrointestinal side effects, most commonly retinal toxicity. Different recommendations for HCQ use in ophthalmology, nephrology and rheumatology guidelines may lead to different approaches among physicians. <h3>Objectives:</h3> The aim of this study was to investigate the reasons for discontinuation of HCQ treatment in patients followed in rheumatology clinic. <h3>Methods:</h3> Between January 2022 and June 2023, the outcomes of patients who were followed up in Rheumatology outpatient clinics of Ankara Bilkent City Hospital and discontinued HCQ treatment were retrospectively evaluated. Comorbidities, HCQ doses and reasons for discontinuation were recorded in detail. <h3>Results:</h3> Of the 140 patients who discontinued HCQ treatment, 93% were women. The mean age of the patients was 54.5±12.9 years. The most common comorbidity was hypertension with 37%, followed by hyperlipidemia 15%, diabetes mellitus 14%, coronary artery disease 7%, arrhythmia 5%, valvular heart disease 3% and chronic kidney disease 3%. At the time of HCQ treatment discontinuation, 36% of patients were receiving steroid treatment. Possible retinal toxicity was the leading reason for discontinuation with 54%, followed by rash (19%), hyperpigmentation (9%) and other reasons (Figure 1) 15%. Only 3 patients voluntarily discontinued HCQ treatment. The rate of patients undergoing dose reduction after retinal toxicity is also very low. <h3>Conclusion:</h3> Consequently, discontinuation of HCQ without objective assessment and approval by a retinopathy specialist may unnecessarily deprive patients of an important medication. It is recommended that HCQ treatment be discontinued more cautiously if necessary based on objective testing. <h3>REFERENCES:</h3> [1] Kim, J. W., Kim, Y. Y., Lee, H., Park, S. H., Kim, S. K., &amp; Choe, J. Y. (2017). Risk of retinal toxicity in longterm users of hydroxychloroquine. The Journal of rheumatology, 44(11), 1674-1679. [2] Stokkermans, T. J., Goyal, A., &amp; Trichonas, G. (2019). Chloroquine and hydroxychloroquine toxicity. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>